for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

EXACT Sciences Corporation

EXAS.O

Latest Trade

83.96USD

Change

0.30(+0.36%)

Volume

318,374

Today's Range

82.59

 - 

84.33

52 Week Range

53.06

 - 

123.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
83.66
Open
83.23
Volume
318,374
3M AVG Volume
41.89
Today's High
84.33
Today's Low
82.59
52 Week High
123.99
52 Week Low
53.06
Shares Out (MIL)
129.83
Market Cap (MIL)
10,861.75
Forward P/E
-51.91
Dividend (Yield %)
--

Next Event

Exact Sciences Corp at Jefferies London Healthcare Conference

Latest Developments

More

Genomic Health Stockholders Approve Proposed Acquisition By Exact Sciences

Exact Sciences Posts Q3 Loss Per Share Of $0.31

Exact Sciences Sees FY 2019 Revenue Of $800 Million To $810 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About EXACT Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Industry

Biotechnology & Drugs

Contact Info

441 Charmany Dr

+1.608.2845700

http://www.exactsciences.com

Executive Leadership

Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

Jeffrey Thomas Elliott

Chief Financial Officer

Mark Stenhouse

President, Cologuard

D. Scott Coward

Senior Vice President, Chief Administrative Officer, General Counsel, Secretary

Graham Peter Lidgard

Senior Vice President, Chief Scientific Officer

Key Stats

1.33 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.3K

2018

0.5K

2019(E)

0.8K
EPS (USD)

2016

-1.630

2017

-0.990

2018

-1.430

2019(E)

-1.615
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.01
Price To Book (MRQ)
14.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
109.19
LT Debt To Equity (MRQ)
66.92
Return on Investment (TTM)
-16.10
Return on Equity (TTM)
-13.21

Latest News

Latest News

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp <EXAS.O> said on Monday it will buy peer Genomic Health Inc <GHDX.O> for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 1300 GMT on Monday:

Exact Sciences to buy Genomic Health for $2.8 billion

Cancer diagnostics company Exact Sciences Corp said on Monday it will buy healthcare company Genomic Health Inc for about $2.8 billion to bolster its cancer testing business.

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

Cancer diagnostics company Exact Sciences Corp <EXAS.O> is in advanced negotiations to buy healthcare company Genomic Health Inc <GHDX.O> for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

Exact Sciences signs marketing deal with Pfizer for cancer test

Exact Sciences Corp said on Wednesday Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer, in a bid to boost sales of the product.

American Cancer Society recommends earlier colorectal cancer screening

The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals.

BRIEF-Exact Sciences Says CEO Kevin T. Conroy's 2017 Total Compensation Was $13.3 Million

* EXACT SCIENCES CORP SAYS CEO KEVIN T. CONROY'S 2017 TOTAL COMPENSATION WAS $13.3 MILLION – SEC FILING Source : https://bit.ly/2w2gEbC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Exact Sciences reports Q1 Loss Per Share of $0.33

* Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S

BRIEF-Mark Stenhouse To Join Exact Sciences As President, Cologuard

* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD

BRIEF-Exact Sciences Q4 Loss Per Share $0.18

* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025

BRIEF-Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025

* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln

* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln

* EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING

BRIEF-Exact Sciences reports qtrly loss per share of $0.23

* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent

Exact Sciences revenue beats on strong Cologuard volumes

Exact Sciences Corp <EXAS.O> reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

BRIEF-Exact Sciences posts Q2 loss per share $0.27

* Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S

BRIEF-Exact Sciences laboratories enters national ancillary provider participation agreement with Unitedhealthcare Insurance

* Exact Sciences Corp -Exact Sciences Laboratories entered national ancillary provider participation agreement with Unitedhealthcare Insurance for cologuard

BRIEF-Exact Sciences says offering of 7 mln common shares priced at $35 per share

* Exact sciences announces pricing of public offering of common stock

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up